Topoisomerase IIα inhibition following DNA transfection greatly enhances random integration in a human pre-B lymphocyte cell line

Biochemical and Biophysical Research Communications

Volumn 382, Issue 3, 2009, Pages 492-496

  Toyoda, Eriko ^a,b   Kurosawa, Aya ^a   Kamekawa, Haruna ^a   Adachi, Noritaka ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NIPPON KAYAKU CO LTD   (Japan)

Author keywords

Gene targeting; Nalm 6; Random integration; Topoisomerase II

Indexed keywords

DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE IIALPHA; DNA TOPOISOMERASE INHIBITOR; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; ENZYME INHIBITOR; TUMOR ANTIGEN;

ARTICLE; B LYMPHOCYTE; CELL CULTURE; CELL GROWTH; CELL LINE; DNA INTEGRATION; DNA TRANSFECTION; ELECTROPORATION; ENZYME INHIBITION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE DELETION; GENETIC RECOMBINATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PRE B LYMPHOCYTE;

ANTIGENS, NEOPLASM; CELL LINE; DNA; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ENZYME INHIBITORS; GENE DELETION; HUMANS; PRECURSOR CELLS, B-LYMPHOID; RECOMBINATION, GENETIC; TRANSFECTION;

EID: 64449087108     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.03.047     Document Type: Article

References (45)

1. Roth D.B., and Wilson J.H. Illegitimate recombination in mammalian cells. In: Kucherlapati R., and Smith G.R. (Eds). Genetic Recombination (1988), American Society for Microbiology, Washington, DC 621-653
2. Moore J.K., and Haber J.E. Cell cycle and genetic requirements of two pathways of nonhomologous end-joining repair of double-strand breaks in Saccharomyces cerevisiae. Mol. Cell Biol. 16 (1996) 2164-2173
3. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 65 (1996) 635-692
4. Sonoda E., Hochegger H., Saberi A., Taniguchi Y., and Takeda S. Differential usage of non-homologous end-joining and homologous recombination in double strand break repair. DNA Repair 5 (2006) 1021-1029
5. Murnane J.P., Yezzi M.J., and Young B.R. Recombination events during integration of transfected DNA into normal human cells. Nucleic Acids Res. 18 (1990) 2733-2738
6. Roth D.B., and Wilson J.H. Relative rates of homologous and nonhomologous recombination in transfected DNA. Proc. Natl. Acad. Sci. USA 82 (1985) 3355-3359
7. Capecchi M.R. Altering the genome by homologous recombination. Science 244 (1989) 1288-1292
8. Fenton M., Bone N., and Sinclair A.J. The efficient and rapid import of a peptide into primary B and T lymphocytes and a lymphoblastoid cell line. J. Immunol. Methods 212 (1998) 41-48
9. Simoes S., Slepushkin V., Gaspar R., Pedroso de Lima M.C., and Duzgunes N. Successful transfection of lymphocytes by ternary lipoplexes. Biosci. Rep. 19 (1999) 601-609
10. Dong K.C., and Berger J.M. Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature 450 (2007) 1201-1205
11. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 3 (2002) 430-440
12. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 28 (1989) 6157-6160
13. Cummings J., and Smyth J.F. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann. Oncol. 4 (1993) 533-543
14. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58 (1989) 351-375
15. Nitiss J.L., and Wang J.C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol. Pharmacol. 50 (1996) 1095-1102
16. Austin C.A., and Marsh K.L. Eukaryotic DNA topoisomerase IIβ. BioEssays 20 (1998) 215-226
17. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70 (2001) 369-413
18. Woessner R.D., Mattern M.R., Mirabelli C.K., Johnson R.K., and Drake F.H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2 (1991) 209-214
19. Padget K., Pearson A.D., and Austin C.A. Quantitation of DNA topoisomerase IIα and β in human leukaemia cells by immunoblotting. Leukemia 14 (2000) 1997-2005
20. Adachi N., Nomoto M., Kohno K., and Koyama H. Cell-cycle regulation of the DNA topoisomerase IIα promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation. Gene 245 (2000) 49-57
21. Akimitsu N., Adachi N., Hirai H., Hossain M.S., Hamamoto H., Kobayashi M., Aratani Y., Koyama H., and Sekimizu K. Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIα. Genes Cells 8 (2003) 393-402
22. Carpenter A.J., and Porter A.C. Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIα mutant human cell line. Mol. Biol. Cell 15 (2004) 5700-5711
23. Christensen M.O., Larsen M.K., Barthelmes H.U., Hock R., Andersen C.L., Kjeldsen E., Knudsen B.R., Westergaard O., Boege F., and Mielke C. Dynamics of human DNA topoisomerases IIα and IIβ in living cells. J. Cell Biol. 157 (2002) 31-44
24. Linka R.M., Porter A.C., Volkov A., Mielke C., Boege F., and Christensen M.O. C-terminal regions of topoisomerase IIα and IIβ determine isoform-specific functioning of the enzymes in vivo. Nucleic Acids Res. 35 (2007) 3810-3822
25. Chaly N., Chen X., Dentry J., and Brown D.L. Organization of DNA topoisomerase II isotypes during the cell cycle of human lymphocytes and HeLa cells. Chromosome Res. 4 (1996) 457-466
26. Ju B.G., Lunyak V.V., Perissi V., Garcia-Bassets I., Rose D.W., Glass C.K., and Rosenfeld M.G. A topoisomerase IIβ-mediated dsDNA break required for regulated transcription. Science 312 (2006) 1798-1802
27. Yang X., Li W., Prescott E.D., Burden S.J., and Wang J.C. DNA topoisomerase IIβ and neural development. Science 287 (2000) 131-134
28. Tsutsui K., Hosoya O., Sano K., and Tokunaga A. Immunohistochemical analyses of DNA topoisomerase II isoforms in developing rat cerebellum. J. Comp. Neurol. 431 (2001) 228-239
29. Tsutsui K., Sano K., Kikuchi A., and Tokunaga A. Involvement of DNA topoisomerase IIβ in neuronal differentiation. J. Biol. Chem. 276 (2001) 5769-5778
30. Lyu Y.L., and Wang J.C. Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIβ. Proc. Natl. Acad. Sci. USA 100 (2003) 7123-7128
31. Zandvliet D.W., Hanby A.M., Austin C.A., Marsh K.L., Clark I.B., Wright N.A., and Poulsom R. Analysis of foetal expression sites of human type II DNA topoisomerase α and β mRNAs by in situ hybridisation. Biochim. Biophys. Acta 1307 (1996) 239-247
32. Onda T., Toyoda E., Miyazaki O., Seno C., Kagaya S., Okamoto K., and Nishikawa K. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors. Cancer Lett. 259 (2008) 99-110
33. Toyoda E., Kagaya S., Cowell I.G., Kurosawa A., Kamoshita K., Nishikawa K., Iiizumi S., Koyama H., Austin C.A., and Adachi N. NK314, a topoisomerase II inhibitor that specifically targets the α isoform. J. Biol. Chem. 283 (2008) 23711-23720
34. Rao V.A., Klein S.R., Agama K.K., Toyoda E., Adachi N., Pommier Y., and Shacter E.B. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIα in breast cancer cells. Cancer Res. 69 (2009) 948-957
35. Snapka R.M., Gao H., Grabowski D.R., Brill D., Chan K.K., Li L., Li G.C., and Ganapathi R. Cytotoxic mechanism of XK469: resistance of topoisomerase IIβ knockout cells and inhibition of topoisomerase I. Biochem. Biophys. Res. Commun. 280 (2001) 1155-1160
36. Iiizumi S., Nomura Y., So S., Uegaki K., Aoki K., Shibahara K., Adachi N., and Koyama H. Simple one-week method to construct gene-targeting vectors: application to production of human knockout cell lines. BioTechniques 41 (2006) 311-316
37. So S., Adachi N., Lieber M.R., and Koyama H. Genetic interactions between BLM and DNA ligase IV in human cells. J. Biol. Chem. 279 (2004) 55433-55442
38. Adachi N., Iiizumi S., So S., and Koyama H. Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage. Biochem. Biophys. Res. Commun. 318 (2004) 856-861
39. Adachi N., Suzuki H., Iiizumi S., and Koyama H. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage. J. Biol. Chem. 278 (2003) 35897-35902
40. Iiizumi S., Kurosawa A., So S., Ishii Y., Chikaraishi Y., Ishii A., Koyama H., and Adachi N. Impact of non-homologous end-joining deficiency on random and targeted DNA integration: implications for gene targeting. Nucleic Acids Res. 36 (2008) 6333-6342
41. Fujimaki K., Aratani Y., Fujisawa S., Motomura S., Okubo T., and Koyama H. DNA topoisomerase II inhibitors enhance random integration of transfected vectors into human chromosomes. Somat. Cell Mol. Genet. 22 (1996) 279-290
42. Aratani Y., Andoh T., and Koyama H. Effects of DNA topoisomerase inhibitors on nonhomologous and homologous recombination in mammalian cells. Mutat. Res. 362 (1996) 181-191
43. Tucker K.L., Beard C., Dausmann J., Jackson-Grusby L., Laird P.W., Lei H., Li E., and Jaenisch R. Germ-line passage is required for establishment of methylation and expression patterns of imprinted but not of nonimprinted genes. Genes Dev. 10 (1996) 1008-1020
44. Uegaki K., Adachi N., So S., Iiizumi S., Koyama H., growth H.i.o.h.K./K.h.d.n.a.c., and repair d.-s.b. or genome integrity. DNA Repair 5 (2006) 303-311
45. Adachi N., So S., Iiizumi S., Nomura Y., Murai K., Yamakawa C., Miyagawa K., and Koyama H. The human pre-B cell line Nalm-6 is highly proficient in gene targeting by homologous recombination. DNA Cell Biol. 25 (2006) 19-24